Research Analysts Offer Predictions for Immunic, Inc.’s Q3 2024 Earnings (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) – Analysts at Leerink Partnrs issued their Q3 2024 earnings estimates for shares of Immunic in a note issued to investors on Monday, September 9th. Leerink Partnrs analyst F. Khurshid forecasts that the company will post earnings of ($0.22) per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunic’s Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.99) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.57) EPS and FY2026 earnings at ($0.41) EPS.

Other equities research analysts also recently issued reports about the stock. B. Riley began coverage on shares of Immunic in a research note on Tuesday, August 27th. They set a “buy” rating and a $6.00 price target for the company. Piper Sandler reiterated an “overweight” rating and set a $28.00 target price on shares of Immunic in a research report on Tuesday, July 16th. StockNews.com upgraded Immunic from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $5.00 price objective on shares of Immunic in a research note on Monday. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $11.20.

Immunic Trading Down 2.0 %

Immunic stock opened at $1.49 on Wednesday. The company has a market cap of $134.22 million, a PE ratio of -0.81 and a beta of 1.82. Immunic has a 1 year low of $0.95 and a 1 year high of $1.92. The company’s 50-day moving average is $1.39 and its two-hundred day moving average is $1.31.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.02. During the same period last year, the business posted ($0.54) EPS.

Hedge Funds Weigh In On Immunic

Hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in Immunic during the 1st quarter worth $25,000. Sierra Summit Advisors LLC bought a new position in shares of Immunic during the 4th quarter valued at about $487,000. Ikarian Capital LLC lifted its holdings in shares of Immunic by 258.3% during the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after purchasing an additional 1,162,378 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after purchasing an additional 1,703,047 shares during the period. Finally, Janus Henderson Group PLC bought a new stake in Immunic during the 1st quarter worth approximately $9,266,000. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.